Segerer Stephan, Böhmig Georg A, Exner Markus, Colin Yves, Cartron Jean-Pierre, Kerjaschki Dontscho, Schlöndorff Detlef, Regele Heinz
Medizinische Poliklinik, Klinikum Innenstadt der Universität, Pettenkoferstrasse 8a, 80336 Munich, Germany.
Transplantation. 2003 Apr 15;75(7):1030-4. doi: 10.1097/01.TP.0000054679.91112.6F.
The Duffy antigen-receptor for chemokines (DARC) is a chemokine-binding protein that is up-regulated on peritubular capillaries (PTC) during cellular renal allograft rejection. C4d deposition and accumulation of inflammatory cells in PTC are indicators of humoral renal allograft rejection. Because DARC is expressed at the site of C4d deposition and might be involved in inflammatory cell recruitment, the authors evaluated the expression of DARC in different forms of human renal allograft rejection.
Deposition of C4d and DARC expression were evaluated by immunohistochemistry in 42 renal transplant biopsy specimens. Biopsy specimens were subdivided according to histologic and immunohistochemical results, that is, C4d-negative biopsy specimens with (Banff 1, n=8) or without signs of cellular rejection (n=16), and C4d-positive biopsies (humoral rejection) with (Banff 1 rejection, n=7) or without cellular rejection (n=11).
DARC expression was found on a small number of PTC and veins in patients without rejection. Cellular and humoral rejection led to a comparable increase in the number of DARC-positive PTC (9.7 and 8.7 vs. 2.6 vessels per high-power field [HPF], respectively). The highest numbers were found in biopsy specimens with signs of both humoral and cellular rejection (17.5 vessels per HPF).
This is the first study that demonstrates an induction of a chemokine-binding protein at the site of C4d deposition in humoral allograft rejection. The additive effect of humoral and cellular rejection on DARC expression might imply different pathways of DARC induction for different forms of allograft rejection.
趋化因子的达菲抗原受体(DARC)是一种趋化因子结合蛋白,在细胞介导的肾移植排斥反应期间,其在肾小管周围毛细血管(PTC)上表达上调。C4d沉积和PTC中炎症细胞的积聚是体液性肾移植排斥反应的指标。由于DARC在C4d沉积部位表达,且可能参与炎症细胞的募集,作者评估了DARC在不同形式的人类肾移植排斥反应中的表达。
通过免疫组织化学对42例肾移植活检标本中的C4d沉积和DARC表达进行评估。活检标本根据组织学和免疫组织化学结果进行细分,即C4d阴性活检标本伴有(Banff 1级,n = 8)或不伴有细胞排斥迹象(n = 16),以及C4d阳性活检标本(体液性排斥反应)伴有(Banff 1级排斥反应,n = 7)或不伴有细胞排斥反应(n = 11)。
在未发生排斥反应的患者中,仅在少数PTC和静脉上发现DARC表达。细胞性和体液性排斥反应导致DARC阳性PTC数量出现类似程度的增加(分别为每高倍视野[HPF]9.7个和8.7个血管,而未发生排斥反应者为2.6个血管)。在同时出现体液性和细胞性排斥反应迹象的活检标本中发现的DARC阳性PTC数量最多(每HPF 17.5个血管)。
这是第一项证明在体液性移植排斥反应中C4d沉积部位诱导趋化因子结合蛋白的研究。体液性和细胞性排斥反应对DARC表达的叠加效应可能意味着不同形式的移植排斥反应中DARC诱导的不同途径。